Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AZ32 + Radiotherapy |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AZ32 | AZ-32|AZ 32 | ATM Inhibitor 13 | AZ32 is an ATM inhibitor, potentially increasing apoptosis and radiosensitization of tumors (PMID: 29769307). | |
| Radiotherapy |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| TP53 M237I | high grade glioma | sensitive | AZ32 + Radiotherapy | Preclinical - Cell culture | Actionable | In a preclinical study, AZ32 treatment increased sensitivity to radiotherapy in malignant glioma cells harboring TP53 M237I in culture, resulting in a greater decrease in cell survival compared to radiation treatment alone (PMID: 29769307). | 29769307 |
| TP53 Q331* | lung non-small cell carcinoma | sensitive | AZ32 + Radiotherapy | Preclinical - Cell line xenograft | Actionable | In a preclinical study, AZ32 treatment increased sensitivity to radiotherapy and demonstrated increased tumor growth inhibition and prolonged survival compared to radiation alone in an intracranial cell line xenograft model of non-small cell lung cancer brain metastasis harboring TP53 Q331* (PMID: 29769307). | 29769307 |
| TP53 R248W | colon carcinoma | predicted - sensitive | AZ32 + Radiotherapy | Preclinical - Cell culture | Actionable | In a preclinical study, AZ32 treatment increased sensitivity to radiotherapy in colon carcinoma cells harboring TP53 R248W compared to radiotherapy alone in culture, resulting in increased mitotic catastrophe; however, wild-type TP53 cells were more sensitive to the treatment combination than TP53 R248W mutant cells (PMID: 29769307). | 29769307 |
| TP53 wild-type | colon carcinoma | sensitive | AZ32 + Radiotherapy | Preclinical - Cell culture | Actionable | In a preclinical study, AZ32 treatment increased sensitivity to radiotherapy in TP53 wild-type colon carcinoma cells compared to radiotherapy alone in culture, and wild-type TP53 cells were more sensitive to the treatment combination than TP53 mutant cells (PMID: 29769307). | 29769307 |
| TP53 wild-type | high grade glioma | predicted - sensitive | AZ32 + Radiotherapy | Preclinical - Cell culture | Actionable | In a preclinical study, AZ32 treatment increased sensitivity to radiotherapy in TP53 wild-type malignant glioma cell lines in culture, however, the effect was smaller compared to the effects in TP53 mutant cell lines (PMID: 29769307). | 29769307 |
| TP53 R175H | high grade glioma | sensitive | AZ32 + Radiotherapy | Preclinical - Cell culture | Actionable | In a preclinical study, AZ32 treatment increased sensitivity to radiotherapy in malignant glioma cells harboring TP53 R175H in culture, resulting in a greater decrease in cell survival and increased mitotic failure compared to radiation treatment alone (PMID: 29769307). | 29769307 |
| TP53 dec exp | high grade glioma | sensitive | AZ32 + Radiotherapy | Preclinical - Cell culture | Actionable | In a preclinical study, shRNA knock-down of TP53 in malignant glioma cells enhanced sensitivity to the combination of AZ32 and radiation compared to TP53 wild-type cells in culture, and resulted in a greater decrease in cell survival and increased mitotic failure compared to either treatment treatment alone (PMID: 29769307). | 29769307 |
| TP53 C238S | high grade glioma | sensitive | AZ32 + Radiotherapy | Preclinical - Cell culture | Actionable | In a preclinical study, AZ32 treatment increased sensitivity to radiotherapy in malignant glioma cells harboring TP53 C238S in culture, resulting in a greater decrease in cell survival compared to radiation treatment alone (PMID: 29769307). | 29769307 |
| TP53 mutant | high grade glioma | predicted - sensitive | AZ32 + Radiotherapy | Preclinical | Actionable | In a preclinical study, AZ32 treatment increased sensitivity to radiotherapy in TP53 mutant mouse glioma cells, resulting in reduced cell survival and impaired DNA damage response in culture, and prolonged survival and significantly increased apoptosis of tumor cells compared to normal brain cells (p<0.01) in syngeneic intracranial tumor models (PMID: 29769307). | 29769307 |
| TP53 D281G | high grade glioma | sensitive | AZ32 + Radiotherapy | Preclinical - Cell line xenograft | Actionable | In a preclinical study, AZ32 treatment increased sensitivity to radiotherapy in malignant glioma cells harboring TP53 D281G, resulting in significantly increased survival (P=0.0015) in intracranial cell line xenograft models compared to radiotherapy alone (PMID: 29769307). | 29769307 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|
CKB BOOST